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epidemiology
incidence
Malignant pleural mesothelioma (MPM) is considered to be a
relatively rare tumour. In Great Britain, the incidence in males is
3.4/100 000, in France it is 2.3/100 000 and in the Netherlands it
is 3.2/100 000. In the last 10 years, the incidence of MPM has
increased slightly, mainly due to the lag time of 30–50 years after
exposure to asbestos and the banning of handling and importing
this product in the late twentieth century. The World Health
Organisation (WHO) estimates asbestos-related disease (ARD)
accounts for 92 250 deaths per year globally [1]. Occupational
exposure to asbestos accounts for more than 80% of the cases and
makes MPM a preventable disease. Although the Western world
is moving towards a levelling-off of ARD incidence, the continued
use of asbestos in the developing world could lead to a global epi-
demic of MPM. Even though asbestos is banned in Europe, other
developed countries have only controlled the import, but not
abolished handling of asbestos products. Recently, a germline
mutation in the BAP1 gene has been linked to predisposition in
some cases of MPM [2]. Somatic mutations may also play a role
in the development of MPM.
diagnosis
Patients typically present with complaints of shortness of
breath, pain and weight loss. These symptoms can occur over a
period of many months. During physical examination, unilateral
effusions are often observed. It is of great importance that a
detailed occupational history is obtained.
Standard work-up includes:
• Chest X-ray
• Computed tomography (CT) scan of chest and upper abdomen
• Thoracentesis, with examination of the pleural effusion
• General laboratory blood tests
Plain chest radiography lacks sufﬁcient sensitivity for routine
staging. Signiﬁcant volumes of pleural effusions can mask
pleural/chest lesions and make small malignant pleural effusions
undetectable.
When an occupational history indicates considerable asbestos
exposure, or the radiology is suggestive of mesothelioma, cy-
tology can be used to detect malignant cells but histological spe-
cimens must often be obtained (see ‘pathology’ section).
A thoracoscopy is recommended to obtain adequate histology,
to optimally stage, and to allow pleural ﬂuid evacuation (with or
without pleurodesis) [3, 4]. This can be performed as a pleuro-
scopy or as video-assisted thoracic surgery (VATS). MPM can be
difﬁcult to identify and it is therefore recommended to obtain bi-
opsies from tissue of both abnormal and normal appearance.
When a thoracoscopy is not feasible or contra-indicated, ultra-
sound-guided true-cut biopsies are a good alternative. Besides a
clinical reason to obtain a diagnosis, there are medico-legal
reasons to conﬁrm the diagnosis of MPM. In Europe, the require-
ments for this vary between countries. To date, there are no
studies that recommend screening of patients who have had any
(occupational) history of asbestos exposure.
Circulating tumour markers have been tested to a great extent
and only a few have been able to facilitate the diagnostic process:
cyfra 21.1, Fibulin-3 and Mesothelin all lack speciﬁcity and
should not be used as speciﬁc markers for mesothelioma [5, 6].
Carcinoembryonic antigen (CEA) is a negative marker and is
not increased in MPM [7]. It can therefore be used to rule out
MPM if cytological/histological analysis is inconclusive.
Recommendation 1
Diagnostic procedures in MPM should encompass at least
• Occupational history with emphasis on asbestos exposure [II, A]
• CT scanning of the thorax [II, A]
• In all patients who have a unilateral pleural thickening, with or
without fluid and/or calcified asbestos plaques, efforts should be
made to obtain a pathological specimen, as there are no specific
clinical features of MPM [II, A]
• There is no place for screening of persons exposed to asbestos [IV, B]
• Tumour markers cannot distinguish MPM [II, B]†Approved by the ESMO Guidelines Committee: December 2004, last update July 2015.
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pathology
The pathological diagnosis of MPM may be difﬁcult for a
number of reasons:
• MPMs are a heterogeneous group of tumours, with the ability
to mimic almost any other form of malignant tumour.
• The three main subtypes (epithelioid, biphasic and sarcoma-
toid) have numerous variants, as described in the 2004 WHO
classiﬁcation [8].
• The pleura is a common site for metastatic disease and react-
ive changes in the pleura may be confused with MPM.
• There are other uncommon benign and malignant pleural
tumours.
Samples for diagnosis may vary widely: pleural effusions, small
(closed) pleural biopsies, image-guided needle core biopsies,
larger open or VATS surgical biopsy samples or debulking speci-
mens. Surgical resection (extrapleural pneumonectomy) is
rarely performed. In some cases, samples may also be obtained
through autopsy.
Signiﬁcant sampling errors can occur in effusion cytology and
small biopsy samples, but also with larger surgical samples
(though less common). Blind biopsies are not recommended
because of risk of complications and are no longer indicated since
the introduction of thoracic ultrasonography.
Cytological features in effusions may permit a diagnosis of
malignancy but reported sensitivities vary widely. When a
biopsy is not possible, appropriate clinical and radiological fea-
tures may assist in suggesting a diagnosis of MPM. Many
mesotheliomas lack signiﬁcant cytological atypia and it is im-
possible to distinguish between benign, reactive mesothelial pro-
liferations and MPM. Cytology sample cells may show variable
atypia (usually low grade) and exhibit a mesothelial immune
phenotype, but malignancy cannot be conﬁrmed. The term
‘atypical mesothelial proliferation’ is useful in this context, but is
insufﬁcient for a diagnosis of MPM. This does not conﬁrm the
diagnosis of MPM, but leaves the possibility open [see below for
ﬂuorescence in situ hybridisation (FISH) testing].
In the vast majority of cases, it is necessary to have adequate
tissue biopsies and the use of appropriate immunohistochemistry
(IHC) for deﬁnitive, primary diagnosis of MPM. Consequently,
deﬁnitive diagnosis of mesothelioma by frozen section is not
recommended.
Tissue biopsy samples the abnormal (mesothelial) cell popu-
lation and permits micro-anatomical assessment of the location
of these cells. This is crucial to identify the extent of invasion.
IHC is pivotal in conﬁrming the mesothelial nature of cells, but
cannot conﬁrm their biological potential (see below). The larger
the tissue biopsy and the more targeted the sampling approach
[radiological or surgical (VATS or open procedure)], the more
reliable and deﬁnitive the diagnosis.
Invasion may be difﬁcult to recognise, especially when tissue
sampling is limited, but identiﬁcation may be assisted by IHC
(see below). Early invasive mesothelioma is particularly difﬁcult,
often disguised by cutting artefacts or the malorientation of sec-
tions, but may be suspected if there is nodular mesothelial cell
proliferation. If deﬁnitive invasion cannot be recognised, the
diagnosis of ‘atypical mesothelial proliferation’ is appropriate,
and further sampling may be indicated. Distinguishing MPM
from organising ﬁbrinous exudates (ﬁbrinous/ﬁbrous pleurisy)
requires a full-thickness biopsy sample, with correct orientation
of histological sections, perpendicular to the pleural surface.
Pathological details of these differential diagnoses are discussed
elsewhere [9, 10].
The most commonly used mesothelial markers are calretinin,
cytokeratin 5/6, WT1 and podoplanin (D240). For (adeno)carcin-
oma, the most useful markers are TTF1, CEA and EP4 [9, 10].
Some markers have been advocated for, due to their distinction of
benign (desmin) versus malignant mesothelial cells (EMA, p53,
GLUT1, IMP3), but these methods lack reliability and are gener-
ally not recommended. Other immunohistochemical markers
may be appropriate, depending on the differential diagnosis in a
particular case. It is worth noting that although pan-cytokeratin
markers are not speciﬁc in any way for mesothelial cells, or malig-
nancy, in the appropriate context, they can be extremely useful in
the diagnosis of sarcomatoid mesothelioma, which often does not
express the usual markers mentioned above.
The use of in situ hybridisation (e.g., FISH) to detect homozy-
gous deletion of p16 is strongly associated with malignancy; it is not
speciﬁc to MPM, but may aid diagnosis [11, 12]. The role of this
technique has yet to be deﬁned and established. Comprehensive
analysis of the genomic landscape of mesothelioma has not yet
been completely deﬁned, however the Tumour Genome Atlas study
is currently underway (www.cancergenome.nih.gov).
Recommendation 2
A. Definitive diagnosis of MPM on effusion cytology specimens
• Effusion cytology for definitive diagnosis of MPM remains a
controversial topic and is still generally not recommended [IV, C].
• If effusion cytology is frankly malignant, the diagnosis may be
strongly suggested but confirmation by biopsy, if possible, is
recommended [A, no level of evidence].
• IHC is invaluable to characterise the nature of atypical effusion cells
and sample preparation to facilitate IHC should be carried out if at
all possible [A, no level of evidence].
B. Definitive diagnosis of MPM on tissue biopsy specimens
• The recognition of tissue invasion is required for definitive diagnosis
of MPM [IV, A].
• Larger and directly targeted biopsy samples facilitate definitive
diagnosis. Surgical-type samples are preferred for diagnosis [IV, A].
• A major subtype diagnosis (epithelioid, biphasic, sarcomatoid)
should be given in all cases of MPM [IV, A].
C. IHC in the diagnosis of MPM
• IHC is recommended for all primary diagnoses of MPM [IV, A].
• At least two ‘mesothelial’ markers and at least two ‘(adeno)
carcinoma’ markers should be used [V, A].
• Sarcomatoid MPM often does not express usual ‘mesothelial’
markers [IV, A].
staging
Staging procedures are standard in all tumours. Staging not only
describes the anatomical extent of a tumour, but it also corre-
lates with prognosis and helps in treatment decision-making. At
least ﬁve staging systems for MPM have been reported. The ﬁrst
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staging system was introduced by Butchart, consisted of four
stages and was based on observations from only 29 patients
[13]. This system was succeeded by others developed by
Mattson, Boutin and Sugarbaker who based their system on
their own experiences. Most of these staging systems had limita-
tions, being based on small numbers of patients. The most
recent system was developed in 1995; it was presented by the
International Mesothelioma Interest Group (IMIG) and is
approved by the Union for International Cancer Control
(UICC) (Table 1) [14]. The limitation of most classiﬁcations is
their inaccuracy in describing tumour (T-) and node (N-)extent.
Most staging systems are based on surgical interventions, as
current imaging techniques have limited resolution. The IMIG
is currently validating a new tumour-node-metastases (TNM)
staging system, using a large retrospective dataset obtained from
centres all over the world.
Although the IMIG staging system could predict prognosis
[15], it failed to be an independent prognostic factor when ana-
lysed in the clinical setting using multivariate analysis [16]. After
the ﬁrst analysis of an IMIG/International Association for the
Study of Lung Cancer (IASLC) database with data from 3101
patients with MPM, several areas of the current staging system
have been deﬁned as requiring modiﬁcation [17]. Multivariable
analyses showed signiﬁcant differences in overall survival (OS)
for most T stages, but not for T2 versus T1. Although a negative
node status was of prognostic importance, no difference between
N1 and N2 was noted.
Disease stage according to the TNM system, when assessed by
surgical staging, is an important predictor of prognosis in
patients with mesothelioma, and the TNM system is therefore
the preferred system.
For decision-making, magnetic resonance imaging (MRI),
using gadolinium, may improve delineation of the tumour with
regard to the surrounding tissues, especially when surgical re-
section is considered to be a part of the treatment plan. This will
also help to visualise foci that may be present in the diaphragm,
pericardium or chest wall [18].
The use of positron emission tomography (PET) scanning is
still under debate because MPM tends to only grow locally and
metastases occur solely in patients with advanced disease.
Discrimination of involved lymph nodes is difﬁcult, due to
anatomy and the limited spatial resolution of current PET scans
[19]. PET scanning can be used in the diagnostic work-up when
PET-avid sites in the thoracic cavity need to be identiﬁed to
obtain representative tissue. Some studies use repeated PET
scanning as a response criterion in addition to the CT scan.
However, no randomised prospective studies have yet been pub-
lished on this. One of the caveats in the evaluation of PET scan-
ning is the false-positive outcome after pleurodesis. This can
result in high activity for a period of more than 6 months after
pleurodesis.
Recommendation 3
Staging for every patient with a confirmed diagnosis of MPM
• In the absence of a uniform, robust and validated staging system,
experts advocate the use of the most recent TNM-based IMIG/UICC
classification [III, B].
• The use of MRI is only recommended in special situations when
tumour delineation is necessary [II, B].
• The use of PET scanning is limited and can be used for localisation
of tumour sites, distant metastases or early response to treatment, as
part of a study protocol [III, B].
front-line therapy for mesothelioma
Front-line chemotherapy improves survival of patients with unre-
sectable MPM. Combination doublet chemotherapy of cisplatin,
with either pemetrexed or raltitrexed, has shown a longer survival
compared with cisplatin alone in randomised phase III trials [20,
21]. Carboplatin is an acceptable alternative to cisplatin and may
be better tolerated in the elderly population [22, 23].
Several phase II clinical trials are investigating the addition of
novel agents to pemetrexed/cisplatin therapy. To date, no agent
has demonstrated superior efﬁcacy. Although the agent CBP501
(a G2 checkpoint abrogator) met its primary end point, it was
not considered to improve upon the efﬁcacy of standard chemo-
therapy. Trials of anti-angiogenic agents such as bevacizumab
or sunitinib [24, 25] have so far failed to demonstrate improve-
ment over standard treatment.
maintenance therapy for mesothelioma
The use of continuation or switch maintenance therapy with
pemetrexed monotherapy has changed practice in the manage-
ment of non-small-cell lung cancer, but is yet to be evaluated in
Table 1. TNM staging according to the International Mesothelioma
Interest Group (IMIG)/Union for International Cancer Control
(UICC) [14]
Stage TNM Comments
Ia T1a N0 M0 Primary tumour limited to ipsilateral parietal
pleura
Ib T1b N0 M0 As stage Ia plus focal involvement of visceral
pleura
II T2 N0 M0 As stage Ia or Ib plus confluent involvement of
diaphragm or visceral pleura or involvement
of the lung
III Any T3 M0 Locally advanced tumour
Any N1 M0 Ipsilateral, bronchopulmonary or hilar lymph
node involvement
Any N2 M0 Subcarinal or ipsilateral mediastinal lymph node
involvement
IV Any T4 Locally advanced, technically unresectable
tumour
Any N3 Contralateral mediastinal, internal mammary,
and ipsilateral or contralateral supraclavicular
lymph node involvement
Any M1 Distant metastases
Reproduced with permission from the American College of Chest
Physicians.
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the mesothelioma setting. However, a phase II trial addressing
this question [NCT01085630], led by the Cancer and Leukemia
Group B (CALGB), is currently underway. Switch maintenance,
with the focal adhesion kinase inhibitor defactinib (VS6063)
versus placebo, is currently under evaluation in the COMMAND
trial [NCT01870609]. Another phase III, switch maintenance,
study of gemcitabine versus observation is currently on-going in
the Netherlands (NVALT 19). A recent phase III study evaluating
switch maintenance to thalidomide was negative [26].
second-line therapy for mesothelioma
There is currently no second-line standard of care. Phase III
evaluation of pemetrexed monotherapy in previously treated
patients was not associated with longer survival when compared
with best supportive care (BSC). Post-study chemotherapy has
been shown to be associated with signiﬁcantly longer survival,
with an adjusted hazard ratio of 0.56 [27]. Single agent vinorel-
bine has shown useful activity in phase II trials [28, 29], demon-
strating a trend towards longer survival as was seen in the ﬁrst-
line study (MSO1) [30].
There are promising developments in the novel agent arena, for
example, anti-mesothelin immunotoxin [31]. Immunotherapy
targeting CTLA4 with tremelimumab [32] is under evaluation in a
large global phase III trial [NCT01843374]. Recent data suggest
that the PDL1, a putative biomarker for PD1/PDL1 therapy, is sig-
niﬁcantly expressed in mesotheliomas, particularly the sarcoma-
toid subtype. In the absence of standard second-line or further-
line therapy, it is recommended that patients are enrolled into
clinical trials.
personalisedmedicine
Individual patient meta-analyses have shown that response to
chemotherapy or progression-free survival (PFS) [33] is corre-
lated with a longer survival. Personalised therapy is therefore
warranted, although currently it is in its infancy.
Mesotheliomas harbouring epigenetically silenced argininosuc-
cinate synthase (AS) are sensitive to arginine-degrading enzymes
pre-clinically. Open label, randomised clinical evaluation of ADI-
PEG 30, in AS-negative patients, has conﬁrmed efﬁcacy with
increased PFS compared with BSC alone. A study to evaluate
ADI-PEG20, in combination with chemotherapy, in AS-negative
mesothelioma [NCT02029690] is underway. Mutation of NF2
occurs in around 50% of mesotheliomas, sensitising inhibition of
FAK [34–36]. Accordingly, this trial is stratifying patients by
Merlin expression.
Recommendation 4
The first- and second-line treatment of unresectable mesothelioma
• Anti-folate/platinum doublet is the only approved standard of care
[I, A].
• Maintenance therapy (switch or continuation) has not yet improved
the OS and patients should be included in these studies [II, A].
• Patients in good condition should be recommended to join studies in
second line [II, A].
radiotherapy
Radiotherapy (RT) can be used for different indications in
mesothelioma: as palliation, as preventive treatment and as part
of a multimodality treatment.
For patients suffering from pain (e.g., by chest wall invasion),
RT, prescribing usually short course regimens, can be considered
although the systematic review by Macleod et al. [37, 38] sug-
gested that no high-quality evidence currently exists to support
RT in treating pain in MPM.
In the case of palliation, the aim of RT is to relieve pain and it
is recommended in cases of inﬁltration of the chest wall or per-
meation nodules by MPM. The treatment is usually given in
short courses such as 1 × 10 or 3 × 8 Gy.
There is much debate whether a scar after thoracoscopy and/
or drainage procedures should be irradiated prophylactically in
order to reduce the likelihood of seeding metastases. It is prob-
ably best to recommend refraining from this procedure unless in
the setting of a clinical trial [39], such as the United Kingdom
‘PIT’ study (ClinicalTrials.gov Identiﬁer NCT01604005).
One randomised trial compared immediate drain site RT (21
Gy in three fractions) to observation in 61 patients treated
between 1998 and 2004 [40]. The authors concluded that
prophylactic drain site RT in MPM did not reduce the incidence
of tumour seeding, as indicated by previous studies conducted
in the 1990s. Quality control of RT, the use of ﬁrst-line therapy
and patient selection can probably explain the discrepancy of
these results. Puncture points or thoracoscopy scars should be
identiﬁed and checked for early irradiation as soon as the diag-
nosis of MPM is conﬁrmed (expert advice). A randomised study
of post-intervention radiation of the tract is accruing in the UK
(PIT trial).
pre- and postoperative RT
Data from the literature are limited and come from retrospective
studies only. In general, it is not recommended that RT is admi-
nistered pre- or postoperatively with large ﬁelds (hemi-thoracic
RT) outside the setting of a clinical trial. The results are poor, in
terms of local control, because of the complex growth patterns
in the diaphragmal gutters and in the lobar ﬁssures. The ﬁeld
size and neighbouring vital organs contribute considerably to
toxicity. Radiation-induced lung toxicity is especially high when
the lung remains in situ after decortication. Improved 3D plan-
ning and the introduction of intensity-modulated RT (IMRT)
seem to overcome most of these issues and allow the remaining
tumour tissue to be properly irradiated. Currently, the ‘SMART’
study is investigating a short accelerated course of high-dose
hemithoracic IMRT followed by extrapleural pneumonectomy
(EPP) [41].
In the absence of phase III randomised trials, the establish-
ment of a prospective controlled study evaluating the efﬁcacy
and tolerability of adjuvant RT post-EPP is recommended. In
this study, a minimum recommended dose of 50 Gy, with a
daily fraction size of 1.8–2 Gy should be given. In one study,
hemithoracic irradiation (54 Gy) was given as adjuvant therapy
after EPP [42]. The local recurrence rate was 13%, with a 4%
local-only recurrence rate. In two other studies, hemithoracic
irradiation, in lower doses, was given as part of a trimodality
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therapy [43, 44]. The local recurrence rate was 50%–60%, with
the highest rate within 12 months after completion of treatment.
One paper addressed the pattern of failure after trimodality
treatment with 3D conformal RT (3DCRT) and highly con-
formal RT (HCRT) in 39 patients. It was concluded that HCRT
was superior to 3DCRT and in-ﬁeld recurrences occurred only
in those treated with 3DCRT (16%). It remains unclear whether
technical issues of surgery, the irradiation or other issues (such
as patient selection) are the reason for this observation. Higher
doses of radiation have resulted in better local control [45]. It is
therefore recommended that this is carried out only in specia-
lised centres (expert advice).
choice of radiation type after EPP
Preliminary results of IMRT in the adjuvant setting after EPP
seemed particularly promising. IMRT may provide good local
control and protect at risk organs such as the heart or liver.
Even after removal of one entire lung, fatal pulmonary toxicity
remained a problem, with six out of 13 patients developing fatal
pneumonitis [46]. To predict the risk of pneumonitis, the pul-
monary dosimetric values V20, V5 and mean lung dose (MLD)
should be speciﬁed: V20 [volume of both lungs minus the plan-
ning target volume (PTV)] should be less than 15% and MLD
should be less than 10 Gy. These dosimetric constraints can also
be used for conformal RT; dose–volume histograms of all target
volumes [clinical target volumes (CTV) and PTV] and of all
critical organs (contralateral lung, cardiac volume, spinal cord,
oesophagus, liver, right and left kidney) should be clearly stated.
With more dosimetric constraints on the residual contralateral
lung, the risk of pneumonitis could be reduced to a minimum
after EPP.
Further studies are needed to better establish the role of RT.
Recent studies have underlined the importance of RT technique,
both in terms of local control and toxicity. It is therefore recom-
mended that RT is delivered in specialised centres (expert
advice).
Recommendation 5
RT can be considered in the following cases
• For palliation of pain related to tumour growth, RT can be
considered [II, A].
• The use of RT to prevent growth in drainage tracts is not proved to
be useful [III, A].
• RT can be given in an adjuvant setting after surgery or
chemo-surgery to reduce the local failure rate. However, no
evidence is available for its use as a standard treatment [II, A].
• When postoperative RT is applied, strict constraints must be adhered
to in order to avoid toxicity to neighbouring organs, and special,
tissue sparing, techniques should be used [II, A].
surgery
Surgery is used for staging procedures or with palliative or cura-
tive intent. Using VATS or thoracoscopy, large biopsy samples
can be obtained for proper pathological, molecular and IHC
analyses. During this procedure, the local extent of the tumour
can be examined. Pleural effusions can be drained and, if
required, a decortication or pleurodesis can be carried out.
surgery for staging and palliation
As most of the staging systems involve the extension of the
tumour on the pleural lining and invasion of muscle layers,
thoracoscopic inspection of the pleural cavity is required.
Besides this intervention, the staging procedure can also be used
to control pleural effusion; perform a talc poudrage or even de-
cortication in the case of a captured lung. One study compared
VATS (partial) pleurectomy versus standard talc poudrage in
196 patients [47]. OS did not improve in the experimental arm,
but control of pleural effusion and quality of life were signiﬁ-
cantly better at 6 and 12 months.
surgery with radical intent
Due to the intricate location and relation to other normal tissues,
it is virtually impossible to obtain free resection margins.
Therefore, the aim of this procedure is to obtain a macroscopic re-
section by removing as much visible tumour as possible, using
different surgical procedures.
Initially, terms like ‘radical’ pleurectomy and decortication
were used without proper description, making comparison
between reported studies difﬁcult. The IASLC established a
working group to recommend uniform deﬁnitions for surgical
procedures dealing with mesothelioma [48]. Currently, a clear
distinction is made between EPP and pleurectomy/decortication
(P/D) with different subcategories:
• EPP implies a complete en bloc removal of the involved parietal
and visceral pleura including the whole ipsilateral lung. If
required, the diaphragm and pericardium can also be resected.
• Extended P/D is the same procedure but the lung is left in situ:
macroscopic complete resection is still the goal.
• P/D refers to removal of all gross tumour, without resection of
the diaphragm or the pericardium.
• A partial pleurectomy entails partial removal of parietal and/
or visceral pleura leaving gross tumour behind.
In a retrospective analysis of data from three large institutions,
663 patients who underwent an EPP or P/D were examined for
survival outcome and toxicity [49]. The operative mortality was
slightly higher (7%) for EPP compared with P/D (4%), with a
higher OS of 16 months for P/D versus 12 months for EPP.
Some studies reported on a trimodality approach in order to
obtain cure. Different combined-modality regimens have been
investigated. Similar to locally advanced lung cancer, induction
chemotherapy was considered to increase the complete resection
rate of early-stage mesothelioma.
A Swiss multicentre trial reported on the additive effect of radi-
ation therapy after a combination of three cycles of cisplatin and
gemcitabine as induction therapy followed by EPP in patients
with resectable MPM [50]. Macroscopic complete resection was
obtained in 37/61 (61%) patients and 36 patients received post-
operative RT. The 90-day mortality was 3.2%, but 62% of patients
experienced one or more complications [empyema (16%) and
bronchopleural ﬁstula (9.5%)].
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Table 2. Summary of recommendations
Diagnosis Recommendation 1
Diagnostic procedures in MPM should encompass at least
• Occupational history with emphasis on asbestos exposure [II, A]
• CT scanning of the thorax [II, A]
• In all patients who have a unilateral pleural thickening, with or without fluid and/or calcified asbestos plaques, efforts should be made
to obtain a pathological specimen, as there are no specific clinical features of MPM [II, A]
• There is no place for screening of persons exposed to asbestos [IV, B]
• Tumour markers cannot distinguish MPM [II, B]
Pathology Recommendation 2
A. Definitive diagnosis of MPM on effusion cytology specimens
• Effusion cytology for definitive diagnosis of MPM remains a controversial topic and is still generally not recommended [IV, C]
• If effusion cytology is frankly malignant, the diagnosis may be strongly suggested but confirmation by biopsy, if possible,
is recommended [A, no level of evidence]
• IHC is invaluable to characterise the nature of atypical effusion cells and sample preparation to facilitate IHC should be carried
out if at all possible [A, no level of evidence]
B. Definitive diagnosis of MPM on tissue biopsy specimens
• The recognition of tissue invasion is required for definitive diagnosis of MPM [IV, A]
• Larger and directly targeted biopsy samples facilitate definitive diagnosis. Surgical-type samples are preferred for diagnosis [IV, A]
• A major subtype diagnosis (epithelioid, biphasic, sarcomatoid) should be given in all cases of MPM [IV, A]
C. IHC in the diagnosis of MPM
• IHC is recommended for all primary diagnoses of MPM [IV, A]
• At least two ‘mesothelial’ markers and at least two ‘(adeno)carcinoma’ markers should be used [V, A]
• Sarcomatoid MPM often does not express usual ‘mesothelial’ markers [IV, A]
Staging Recommendation 3
Staging for every patient with a confirmed diagnosis of MPM
• In the absence of a uniform, robust and validated staging system, experts advocate the use of the most recent TNM-based IMIG/UICC
classification [III, B]
• The use of MRI is only recommended in special situations when tumour delineation is necessary [II, B]
• The use of PET scanning is limited and can be used for localisation of tumour sites, distant metastases or early response to treatment,
as part of a study protocol [III, B]
Personalised
medicine
Recommendation 4
The first- and second-line treatment of unresectable mesothelioma
• Anti-folate/platinum doublet is the only approved standard of care [I, A]
• Maintenance therapy (switch or continuation) has not yet improved the OS and patients should be included in these studies [II, A]
• Patients in good condition should be recommended to join studies in second line [II, A]
Radiotherapy Recommendation 5
RT can be considered in the following cases
• For palliation of pain related to tumour growth, RT can be considered [II, A]
• The use of RT to prevent growth in drainage tracts is not proved to be useful [III, A]
• RT can be given in an adjuvant setting after surgery or chemo-surgery to reduce the local failure rate. However, no evidence is available
for its use as a standard treatment [II, A]
• When postoperative RT is applied, strict constraints must be adhered to in order to avoid toxicity to neighbouring organs and special,
tissue sparing, techniques should be used [II, A]
Surgery Recommendation 6
The indications for surgery are
• For palliation of pleural effusions when chest tube drainage is not successful [II, A]
• To obtain diagnostic samples of tumour tissue and to stage the patient [II, A]
• To be part of a multimodality treatment, preferably as part of a study [II, A]
• To perform a macroscopic complete resection by means of P/D or EPP [III, C]
MPM, malignant pleural mesothelioma; CT, computed tomography; IHC, immunohistochemistry; TNM, tumour-node-metastasis; IMIG, International
Mesothelioma Interest Group; UICC, Union for International Cancer Control; MRI, magnetic resonance imaging; PET, positron emission tomography;
OS, overall survival; RT, radiotherapy; P/D, pleurectomy/decortication; EPP, extrapleural pneumonectomy.
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For the patients undergoing EPP, an encouraging median
survival time of 23 months was obtained.
In another retrospective study of trimodality therapy, 60
patients underwent induction chemotherapy (cisplatin/anti-
folate in 30 patients), followed by EPP and postoperative RT to
50 Gy [51]. The full treatment protocol could be applied in half
of the patients.
The European Organisation for Research and Treatment of
Cancer (EORTC) studied the feasibility of trimodality therapy
in a phase II trial (EORTC 08031) with clearly deﬁned timelines
[52]. Patients with pathologically proven mesothelioma (up to
stage cT3N1M0) received induction chemotherapy (cisplatin
and pemetrexed × 3) followed by EPP within 21–56 days after
the last dose of chemotherapy, in the absence of progressive
disease and unacceptable toxicity.
A ‘success of treatment’ was deﬁned as a patient who had
received the full protocol and was alive after 90 days without
progressive disease and without grade 3 or 4 toxicity. Of the 57
patients included, 42 had EPP (73.7%) after induction therapy.
The 90-day mortality was 6.5%, with an OS of 18.4 months and
progression-free median survival of 13.9 months. Only 24
patients (42.1%) met the deﬁnition of success, and therefore the
primary end point was not reached.
A similar phase II trial in the USA, but without predeﬁned
time limits, included 77 patients from nine institutions. The op-
erative mortality was 7% and median OS was 16.8 months [53].
Although trimodal therapy seemed feasible in selected
patients with promising results, this concept was tested in the
UK with the Mesothelioma and Radical Surgery 1 (MARS 1)
trial. MARS 1 was designed as a randomised trial between EPP
and no EPP after induction chemotherapy. In the feasibility
study, 112 patients were entered in 11 centres, during a 3-year
period. Only 50 patients (45%) could be randomised after in-
duction therapy and 16 patients were randomly assigned to
receive EPP. In this small group, there were three case fatalities,
giving a mortality rate of 18.8% [54]. The median OS for
patients undergoing EPP was 14 months, compared with 19
months for those not having EPP. It was concluded by the
authors that trimodality therapy offers no beneﬁt and in fact
may harm patients. Therefore, a further study, MARS 2, was
designed to assess the feasibility of randomisation into P/D and
not EPP.
In a systematic review of EPP for mesothelioma, carried out in
2010, 34 studies from 26 institutions were evaluated [55]. Median
OS after EPP varied from 9.4 to 27.5 months, with a 5-year sur-
vival rate from 0% to 24%. Overall mortality ranged from 0% to
11.8% and morbidity from 22% to 82%. The conclusion of this sys-
tematic review was that selected patients might beneﬁt from EPP,
especially when combined with induction or adjuvant therapy.
The safety and efﬁcacy of trimodality treatment was assessed
in a systematic review encompassing 16 studies (including 5
prospective trials). The median OS ranged from 12.8 to 46.9
months with perioperative mortality from 0% to 12.5% [56].
The authors concluded that trimodality therapy may offer ac-
ceptable perioperative outcomes and long-term survival in
selected patients treated in specialised centres.
A multidisciplinary team with sufﬁcient experience should
provide recommendations on the suitability of patients for
trimodality therapy.
Recommendation 6
The indications for surgery are
• For palliation of pleural effusions when chest tube drainage is not
successful [II, A].
• To obtain diagnostic samples of tumour tissue and to stage the
patient [II, A].
• To be part of a multimodality treatment, preferably as part of a
study [II, A].
• To perform a macroscopic complete resection by means of P/D or
EPP [III, C].
response evaluation and follow-up
It is advised that response evaluation is performed with CT
scanning and the examinations performed at presentation.
The follow-up of a patient will depend on the local recom-
mendations or as dictated by the protocol in case of study
participation.
methodology
These clinical practice guidelines were developed in accordance
with the ESMO standard operating procedures for clinical practice
guidelines development. The relevant literature has been selected
by the expert authors. A summary of recommendations is shown
in Table 2. Levels of evidence and grades of recommendation have
Table 3. Levels of evidence and grades of recommendation
(adapted from the Infectious Diseases Society of America-United
States Public Health Service Grading Systema)
Levels of evidence
I Evidence from at least one large randomised, controlled trial
of good methodological quality (low potential for bias) or
meta-analyses of well-conducted randomised trials without
heterogeneity
II Small randomised trials or large randomised trials with a suspicion
of bias (lower methodological quality) or meta-analyses of such
trials or of trials with demonstrated heterogeneity
III Prospective cohort studies
IV Retrospective cohort studies or case–control studies
V Studies without control group, case reports, experts opinions
Grades of recommendation
A Strong evidence for efficacy with a substantial clinical benefit,
strongly recommended
B Strong or moderate evidence for efficacy but with a limited clinical
benefit, generally recommended
C Insufficient evidence for efficacy or benefit does not outweigh the
risk or the disadvantages (adverse events, costs, etc.), optional
D Moderate evidence against efficacy or for adverse outcome,
generally not recommended
E Strong evidence against efficacy or for adverse outcome, never
recommended
aBy permission of the Infectious Diseases Society of America [57].
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been applied using the system shown in Table 3. Statements
without grading were considered justiﬁed standard clinical practice
by the experts and the ESMO faculty. This manuscript has been
subjected to an anonymous peer-review process.
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